<div id="readability-page-1"><h3>Easter Sale - 70% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>Jinxin Fertility Group Ltd. ( (HK:1951) ) has shared an update. Jinxin Fertility Group Limited has cancelled 52,662,000 shares that it previously repurchased under general mandates granted in 2024 and 2025, reducing its total issued share capital from 2,757,706,043 to 2,705,044,043 shares. The board expects the cancellation of these repurchased shares to enhance net asset value and earnings per share and plans to continue using a similar cancel-and-retire approach for buybacks during 2026, signaling an ongoing focus on shareholder value. The move underscores the company’s capital management strategy at a time when fertility and reproductive healthcare providers are competing to differentiate themselves in the market. By shrinking the share base, Jinxin Fertility aims to strengthen its financial metrics and potentially improve its appeal to investors, while retaining flexibility to repeat such cancellations as future repurchases are executed. The most recent analyst rating on (HK:1951) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page. More about Jinxin Fertility Group Ltd. Jinxin Fertility Group Limited is a Cayman Islands-incorporated company listed in Hong Kong that operates in the fertility and assisted reproductive services sector. The group focuses on providing medical treatments and related services for fertility patients, positioning itself within the growing reproductive healthcare market in China and broader Asia. Average Trading Volume: 22,615,482 Technical Sentiment Signal: Hold Current Market Cap: HK$6.86B </div>

LABU

159849

Jinxin Fertility Group Ltd. has cancelled 52.7 million repurchased shares, reducing its total issued share capital to 2.7 billion shares. This move aims to enhance net asset value and earnings per share, reflecting the company's commitment to shareholder value. The company plans to continue this strategy for future buybacks. Currently, the stock holds a Hold rating with a price target of HK$2.50. Jinxin operates in the fertility and assisted reproductive services sector, focusing on the growing reproductive healthcare market in Asia.

Tip Ranks

Direxion S&P Biotech Bull 3X

INVO Fertility

China Merchants CSI Biotechnology Theme ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

iShares US Medical Devices

China Merchants CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI Biotechnology Theme ETF

SPDR S&P Health Equip

iShares Biotechnology ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares US Healthcare Providers

ChinaAMC CSI All Share Health Care Devices ETF

ALPS Medical Breakthrough

ChinaAMC CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Health

Minsheng Royal CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

iShares Global Healthcare

VG Health

Jinxin Fertility Cancels 52.7 Million Repurchased Shares to Lift Per-Share Metrics